ESTRO ACROP consensus guideline on implementation and practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer
ESTRO ACROP consensus guideline on implementation and practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer
复制标题
DOI：
10.1016/j.radonc.2017.05.012
复制
发表时间：
2017-07-01
影响因子：
5.7
通讯作者：
Verellen, Dirk
中科院分区：
文献类型：
--
作者：
Guckenberger, Matthias;Andratschke, Nicolaus;Verellen, Dirk
背景：立体定向全身放射治疗(SBRT)已成为不能手术的早期非小细胞肺癌(NSCLC)患者和拒绝手术切除患者的标准治疗方案。方法：ESTRO ACROP指南基于问卷调查，涵盖了SBRT实施和实践的所有方面(n=114项)。问卷由ESTRO课程“影像引导下SBRT的临床实践与实施”的11名教职员工和他们所在的8个机构完成。结果：72%的项目得到了50%机构的认可。只有8/57的技术和技术被确定为SBRT的强制性技术，而32/57被认为是可选的。相比之下，在12/24个项目中，与质量保证有关的内容被认为是强制性的。对于周围部位的病变，采用3×15的剂量和4×12的剂量(PTV D95-D99；D-max)，获得了适合风险的SBRT分割的共识
Background: Stereotactic body radiotherapy (SBRT) has become the standard of care for medically inoperable patients with peripherally located, early stage non-small cell lung cancer (NSCLC), and for those refusing surgical resection. Despite the availability of national and international guidelines, there exists substantial variability in many aspects of SBRT practice.Methods: The ESTRO ACROP guideline is based on a questionnaire covering all aspects of SBRT implementation and practice (n = 114 items). The questionnaire was answered by the 11 faculty members of the ESTRO course "Clinical practice and implementation of image-guided SBRT" and their 8 institutions.Results: Agreement by >50% of the institutions was achieved in 72% of all items. Only 8/57 technologies and techniques were identified as mandatory for SBRT while 32/57 were considered as optional. In contrast, quality-assurance related elements were considered as mandatory in 12/24 items. A consensus of risk-adapted SBRT fractionation was achieved with 3 x 15 Gy for peripherally located lesions and 4 x 12 Gy (PTV D95-D99; D-max